Sandbox Diclofenamide

Sandbox Diclofenamide
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

Warning See full prescribing information for complete Boxed Warning. Condition Name: (Content)

Overview

Sandbox Diclofenamide is a Adrenergic receptor agonist that is FDA approved for the {{{indicationType}}} of elevated intraoculr pressure. There is a Black Box Warning for this drug as shown here. Common adverse reactions include anorexia, nausea, vomiting, drowsiness, paresthesias.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Elevated Intraoculr Pressure

• Dosing Information

• Recommended initial dosage: 100-200 mg PO bid
• Recommended maintenence dosage: 25-50 mg PO qd or bid or tid

Off-Label Use and Dosage (Adult)

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Sandbox Diclofenamide FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Contraindications

• Hepatic Insufficiency

• DARANIDE® (dichlorphenamide tablets USP) is contraindicated in hepatic insufficiency.

• Electrolyte Imbalance

• DARANIDE® is contraindicated in renal failure, adrenocortical insufficiency, hyperchloremic acidosis, or in conditions in which serum levels of sodium or potassium are depressed.

• Obstructive Pulmonary Disease

• DARANIDE® should not be used in patients with severe pulmonary obstruction who are unable to increase their alveolar ventilation since their acidosis may be increased.

• Hypersensitivity

• DARANIDE® is contraindicated in patients who are hypersensitive to this product.

Warnings

Warning See full prescribing information for complete Boxed Warning. Condition Name: (Content)

Hypokalemia

Potassium excretion is increased by DARANIDE® (dichlorphenamide tablets USP) and hypokalemia may develop. Interference with adequate oral electrolyte intake will also contribute to hypokalemia. Hypokalemia can sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular irritability). Hypokalemia may be avoided or treated by use of potassium supplements such as foods with a high potassium content.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Sandbox Diclofenamide Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Sandbox Diclofenamide Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Sandbox Diclofenamide Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Sandbox Diclofenamide in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Sandbox Diclofenamide in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Sandbox Diclofenamide during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Sandbox Diclofenamide in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Sandbox Diclofenamide in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Sandbox Diclofenamide in geriatric settings.

Gender

There is no FDA guidance on the use of Sandbox Diclofenamide with respect to specific gender populations.

Race

There is no FDA guidance on the use of Sandbox Diclofenamide with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Sandbox Diclofenamide in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Sandbox Diclofenamide in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Sandbox Diclofenamide in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Sandbox Diclofenamide in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Sandbox Diclofenamide Administration in the drug label.

Monitoring

There is limited information regarding Sandbox Diclofenamide Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Sandbox Diclofenamide and IV administrations.

Overdosage

There is limited information regarding Sandbox Diclofenamide overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Sandbox Diclofenamide Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Sandbox Diclofenamide Mechanism of Action in the drug label.

Structure

There is limited information regarding Sandbox Diclofenamide Structure in the drug label.

Pharmacodynamics

There is limited information regarding Sandbox Diclofenamide Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Sandbox Diclofenamide Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Sandbox Diclofenamide Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Sandbox Diclofenamide Clinical Studies in the drug label.

How Supplied

There is limited information regarding Sandbox Diclofenamide How Supplied in the drug label.

Storage

There is limited information regarding Sandbox Diclofenamide Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Sandbox Diclofenamide |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Sandbox Diclofenamide |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Sandbox Diclofenamide Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Sandbox Diclofenamide interaction has not been established. Talk to your doctor regarding the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Sandbox Diclofenamide Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Sandbox Diclofenamide Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.